Acute myocardial infarction and cardiogenic shock: Prognostic impact of cytokines: INF-γ, TNF-α, MIP-1β, G-CSF, and MCP-1β;Akuter Myokardinfarkt und kardiogener Schock: Prognostischer Einfluss von Zytokinen: INF-γ, TNF-α, MIP-1β, G-CSF und MCP-1β

Medizinische Klinik - Intensivmedizin und Notfallmedizin

Volumn 107, Issue 6, 2012, Pages 476-484

  Prondzinsky, R ^a   Unverzagt, S ^a   Lemm, H ^a   Wegener, N ^a   Heinroth, K ^a   Buerke, U ^a   Fiedler, M ^b   Thiery, J ^b   Haerting, J ^a   Werdan, K ^a   Buerke, M ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Biological markers; Cardiomyocytes; Inflammation; Mortality determinants; Multiple organ dysfunction syndrome

Indexed keywords

ACETYLSALICYLIC ACID; CATECHOLAMINE; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOGENIC SHOCK; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY HEMODYNAMICS; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; LOADING DRUG DOSE; MALE; MEASUREMENT; MORTALITY; MULTIPLE ORGAN FAILURE; PARAMETERS; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

EID: 84879578464     PISSN: 21936218     EISSN: 21936226     Source Type: Journal    
DOI: 10.1007/s00063-012-0117-y     Document Type: Article

References (51)

1. Prondzinsky R, Lemm H, Swyter M et al (2010) Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome. Crit Care Med 38: 152-160.
2. Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341: 625-634.
3. Ruiz-Bailen M, Rucabado-Aguilar L, Exposito-Ruiz M et al (2009) Cardiogenic shock in acute coronary syndrome. Med Sci Monit 15: RA57-66.
4. Goldberg RJ, Spencer FA, Gore JM et al (2009) Thirty-year trends (1975-2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 119: 1211-1219.
5. Théroux P, Armstrong PW, Mahaffey KW et al (2005) Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 26: 1964-1970.
6. Hon-KanYip, Ali A Youssef, Li-Teh Chang et al (2007) Association of Interleukin-l0 level with increased 30-day mortality in patients with ST-Segmen elevation acute myocardial infarction undergoing primary coronary intervention. Circ J 71: 1086-1091.
7. Tan J, Hua Q, Li J, Fan Z (2009) Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction. Heart Vessels 24: 329-334.
8. Debrunner M, Schuiki E, Minder E et al (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97: 298-305.
9. Hasper D, Hummel M, Kleber FX et al (1998) Systemic inflammation in patients with heart failure. Eur Heart J 19: 761-765.
10. Appoloni O, Dupont E, Vandercruys M et al (2004) Association between the TNF-2 allele and a better survival in cardiogenic shock. Chest 125: 2232-2237.
11. Malleo G, Mazzon E, Genovese T et al (2008) Absence of endogenous interleukin-10 enhanced organ dysfunction and mortality associated to zymosan-induced multiple organ dysfunction syndrome. Cytokine 41: 136-143.
12. Prinsen JH, Baranski E, Posch H et al (2008) Interleukin-6 as diagnostic marker for neonatal sepsis: determination of access IL-6 cutoff for newborns. Clin Lab 54: 179-183.
13. Werdan K, Hettwer S, Bubel S et al (2009) Septic circulatory shock and septic cardiomyopathy. Internist (Berl) 50: 799-800, 802-806, 808-809.
14. Werdan K, Schmidt H, Ebelt H et al (2009) Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol 87: 266-274.
15. Shpektor A (2010) Cardiogenic shock: the role of inflammation. Acute Card Care 12: 115-118.
16. TRIUMPH Investigators, Alexander JH, Reynolds HR et al (2007) Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA 297: 1657-1666.
17. Locksley RM, Killeen N, Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
18. Michie HR, Manogue KR, Spriggs DR et al (1988) Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318: 1481-1486.
19. Levine B, Kalman J, Mayer L et al (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323: 236-241.
20. Suffredini AF, Fromm RE, Parker MM et al (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321: 280-287.
21. Reithmann C, Werdan K (1994) Tumor necrosis factor alpha decreases inositol phosphate formation and phosphatidylinositol-bisphosphate (PIP2) synthesis in rat cardiomyocytes. Naunyn Schmiedebergs Arch Pharmacol 349: 175-182.
22. Müller-Werdan U, Schumann H, Loppnow H et al (1998) Endotoxin and tumor necrosis factor alpha exert a similar proinflammatory effect in neonatal rat cardiomyocytes, but have different cardiodepressant profiles. J Mol Cell Cardiol 30: 1027-1036.
23. Müller-Werdan U, Engelmann H, Werdan K (1998) Cardiodepression by tumor necrosis factor-alpha. Eur Cytokine Netw 9: 689-691.
24. Pestka S (2007) The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem 282: 20047-20051.
25. Szkodzinski J, Hudzik B, Osuch M et al (2010) Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Heart Vessels 26: 399-407.
26. Metcalf D, Di Rago L, Mifsud S et al (2000) The development of fatal myocarditis and polymyositis in mice heterozygous for IFN-γ and lacking the SOCS-1 gene. Proc Natl Acad Sci U S A 97: 9174-9179.
27. Khakoo AY, Halushka MK, Rame JE et al (2005) Reversible cardiomyopathy caused by administration of interferon alpha. Nat Clin Pract Cardiovasc Med 2: 53-57.
28. Clements JM, Craig S, Gearing AJ et al (1992) Biological and structural properties of MIP-1 alpha expressed in yeast. Cytokine 4: 76-82.
29. Broxmeyer HE, Sherry B, Cooper S et al (1993) Comparative analysis of the human macrophage inflammatory protein family of cytokines (chemokines) on proliferation of human myeloid progenitor cells. Interacting effects involving suppression, synergistic suppression, and blocking of suppression. J Immunol 150: 3448.
30. Roussoulières AL, Raisky O, Chalabreysse L et al (2005) Identification and characterization of two genes (MIP-1beta, VE-CADHERIN) implicated in acute rejection in human heart transplantation: use of murine models in tandem with cDNA arrays. Circulation 111: 2626-2644.
31. Roffe E, Souza AL, Caetona BC et al (2006) A DNA vaccine encoding CCL4/MIP-1beta enhances myocarditis in experimental Trypanosoma cruzi infection in rats. Microbes Infect 8(12-13): 2745-55.
32. Yadav A, Saini V, Arora S (2010) MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 411: 1570-1579.
33. Lemos JA de, Morrow DA, Blazing MA et al (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes. Results from the A to Z Trial. J Am Coll Cardiol 50: 2117-2124.
34. Frangogiannis NG (2007) The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol 50: 2125-2127.
35. Shim W, Mehta A, Lim SY et al (2011) G-CSF for stem cell therapy in acute myocardial infarction: friend or foe? Cardiovasc Res 89: 20-30.
36. Achilli F, Malafronte C, Lenatti L et al (2010) Granulocyte colony-stimulating factor attenuates left ventricular remodelling after acute anterior STEMI: results of the single-blind, randomized, placebo-controlled multicentre STem cEll Mobilization in Acute Myocardial Infarction (STEM-AMI) Trial. Eur J Heart Fail 12: 1111-1121.
37. Steppich BA, Demetz G, Schulz S et al (2011) Effects of G-CSF on systemic inflammation, coagulation and platelet activation in patients with acute myocardial infarction. Thromb Res 127: 119-121.
38. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41.
39. Altman DA (1991) Practical statistics for medical research. Chapman and Hall, London.
40. Norozi K, Buchhorn R, Wessel A et al (2008) Beta-blockade does not alter plasma cytokine concentrations and ventricular function in young adults with right ventricular dysfunction secondary to operated congenital heart disease. Circ J 72: 747-752.
41. Loppnow H, Zhang L, Buerke M et al (2011) Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures. J Cell Mol Med 15: 994-1004.
42. Sukumaran V, Watanabe K, Veeraveedu PT et al (2011) Olmesartan, an AT(1) antagonist, attenuates oxidative stress, endoplasmic reticulum stress and cardiac inflammatory mediators in rats with heart failure induced by experimental autoimmune myocarditis. Int J Biol Sci 7: 154-167.
43. Buys ES, Cauwels A, Raher MJ et al (2009) sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models. Am J Physiol Heart Circ Physiol 297: H654-663.
44. Hohensinner PJ, Niessner A, Huber K et al (2011) Inflammation and cardiac outcome. Curr Opin Infect Dis 24: 259-264.
45. Werra I de, Zanetti G, Jaccard C et al (2001) CD14 expression on monocytes and TNF alpha production in patients with septic shock, cardiogenic shock or bacterial pneumonia. Swiss Med Wkly 131: 35-40.
46. Adrie C, Adib-Conquy M, Laurent I et al (2002) Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome. Circulation 106: 562-568.
47. Unverzagt S, Machemer M. T, Solms A et al (2011) Intra-aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock. Cochrane Library: CD007398.
48. Thiele H, Sick P, Boudriot E et al (2005) Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 26: 1276-1283.
49. Burkhoff D, Cohen H, Brunckhorst C et al (2006) A randomized multicenter clinical study to evaluate the safety and efficacy of the Tandem Heart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 152: 469 (e1-8).
50. Seyfarth M, Sibbing D, Bauer I et al (2008) A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52: 1584-1588.
51. Jung C, Lauten A, Rödiger C et al (2009) Effect of intra-aortic balloon pump support on microcirculation during high-risk percutaneous intervention. Perfusion 24: 417-421.